GMED Medical Devices · Spine surgery · Robotics · Medical devices · Thesis updated July 19, 2026

Spine momentum, now priced for execution

Q1 2026 net sales were $759.9 million, up 27.0% from the prior year quarter.
U.S. Spine grew 10% for the third straight quarter, a clear sign of share gains.
Management raised 2026 non-GAAP EPS guidance to $4.70 to $4.80 while keeping revenue guidance in place.
Enabling Technologies revenue was $26.9 million in Q1, but more lease and rental deals may lower upfront sales.
Nevro added $67.2 million of U.S. sales in Q1, but management still expects a choppy 2026 top line.

01 Running thesis

Share gains with a higher bar

Globus is doing what investors wanted after the NuVasive and Nevro deals. It is growing the core spine business, lifting margins, and turning acquired assets into earnings faster than planned. Q1 2026 made that clearer: total net sales rose 27.0% to $759.9 million, and U.S. Spine grew 10% for the third straight quarter.

The bull case is that Globus is building a closed system for spine surgery. Its robots and navigation tools help place implants. The implants then create repeat sales each time a surgeon uses the system. The new patient-specific script platform adds another piece to that system, because it ties custom implants into the same technology stack.

The bear case is now less about whether Globus can integrate deals at all. It is more about whether this level of execution can last. U.S. Spine must hold up against harder comparisons. Enabling Technologies may face a near-term revenue gap as more hospitals choose leases or rentals instead of buying systems upfront. Nevro is profitable sooner than planned, but its revenue is still being reset and may not normalize until later in 2026.

Finn’s view is positive but not one-sided. The company has strong financial health and a better cost story than it had a year ago. The stock still needs proof that 10% U.S. Spine growth, margin gains, and Nevro stabilization can all happen at the same time.

May 2026▲Q1 confirmed the late-2025 rebound. U.S. Spine grew 10% again, Enabling Technologies rose to $26.9 million, and management lifted 2026 non-GAAP EPS guidance to $4.70 to $4.80.

May 2026→The Q1 2026 10-Q confirmed $759.9 million of total net sales and $67.2 million of U.S. Nevro sales. It also said risk factors had no material changes from the 2025 Form 10-K.

Feb 2026▲Q4 2025 strengthened the case that acquisition risk had fallen. Globus said it had actioned $200 million of NuVasive synergies ahead of plan and that Nevro became accretive 15 months earlier than first expected.

Nov 2025▲Q3 2025 was a major beat-and-raise quarter. Total net sales rose 22.9%, U.S. Spine grew 10%, and free cash flow reached a record non-GAAP $213.9 million.

Aug 2025▲Q2 2025 showed the supply chain issues from Q1 were easing. U.S. Spine grew 7.4% on a day-adjusted basis, and Enabling Technologies recovered from Q1, though sales cycles stayed longer.

May 2025▼Q1 2025 set the original risk frame. Sales were slightly down on a constant currency basis as soft enabling tech sales and integration disruption offset early signs of U.S. Spine momentum.

02 Business model

Implants pulled by robots

Globus makes money by selling implants, tools, biologics, trauma products, neuromonitoring services, and chronic pain stimulation systems. The key profit engine is spine implants. These are used in surgeries where doctors stabilize or repair the spine.

Its Enabling Technologies business sells or places imaging, navigation, and robotic systems such as ExcelsiusGPS. These systems are expensive capital equipment, so sales can jump around by quarter. The strategic goal is not only the robot sale. The bigger prize is implant pull-through, which means more Globus implants used in each procedure because the surgeon works inside the Globus system.

The company also has supply chain control. The internal view says about 95% of production is based in the U.S., which can help with quality, speed, and tariff exposure. That does not remove risk, but it gives Globus more control than a device maker that depends heavily on overseas production.

Nevro extends the model into chronic pain care. Its spinal cord stimulation systems treat pain with electrical pulses rather than spine surgery. If Globus can fix Nevro’s sales base, it could capture more of the patient journey before and after surgery.

03 Product portfolio

The tools in the system

Growth engine

U.S. Spine implants

This is the core engine. Products include expandable spacers, MIS screws, lateral and ACDF platforms, and fixation systems.

Option

ExcelsiusGPS and Enabling Technologies

These are robotic, imaging, and navigation systems used to guide surgery. Sales can be uneven, but each placement can support future implant use.

Option

Script patient-specific implants

Globus received 510(k) clearance for a patient-specific spacer and rod system. The early question is whether surgeons adopt it beyond a small set of complex cases.

Steady

Trauma and NSO

This smaller group includes trauma, neurosurgery, and orthopedic products. Management has said underlying trauma demand is strong, though integration work has caused some disruption.

Option

Nevro neuromodulation

Nevro sells high-frequency spinal cord stimulation systems for chronic pain. It added $67.2 million of U.S. sales in Q1 2026, but the sales base is still being rebuilt.

04 Business segments

Mostly musculoskeletal sales

Musculoskeletal Solutions96%growing fast

Enabling Technologies4%growing fast

The mix uses Q1 2026 net sales of $759.9 million. Globus reports one reportable segment, but it describes two product and service categories: Musculoskeletal Solutions and Enabling Technologies.

05 Risk factors

What could break the story

U.S. Spine growth slows

High impact · Medium odds

U.S. Spine has grown 10% for three straight quarters. That is well above the spine market growth rate described in the internal view. If the gains came mainly from recruiting reps or easy account wins, growth could slow as comparisons get tougher.

We watchQuarterly U.S. Spine growth, plus management comments on rep recruiting, cross-selling, and robotic pull-through.

Lease strategy creates a sales gap

Medium impact · Medium odds

Management is shifting more Enabling Technologies deals toward leases and rentals. That may speed system placements, but it can reduce upfront revenue versus outright sales. The long-term payoff depends on enough implant revenue following those placements.

We watchEnabling Technologies revenue, new system placements, and the mix of sales versus leases and rentals.

Nevro revenue does not trough

Medium impact · Medium odds

Nevro became accretive to earnings earlier than expected, which lowers profit risk. The revenue story is still not fixed. Management expects a more normal run rate in the second half of 2026, so a delay would hurt confidence in the deal.

We watchNevro quarterly sales, sales force hiring, and any change to the expected second-half 2026 recovery.

Margins stop improving

High impact · Low odds

The Q1 beat was not only about sales. Management raised 2026 non-GAAP EPS guidance to $4.70 to $4.80 while keeping revenue guidance in place. That signals confidence in cost savings and manufacturing gains, but investors will punish a miss because the stock now expects execution.

We watchAdjusted gross margin, non-GAAP EPS guidance, and updates on NuVasive and Nevro synergy capture.

Robotics competition tightens

Medium impact · Medium odds

Spine surgery is competitive, and robotics is a key battleground. Globus has an integrated system, but rivals can still compete on surgeon relationships, pricing, features, and hospital contracts. If new systems reduce Globus placements, implant pull-through could weaken.

We watchExcelsiusGPS placement trends, hospital contract wins, and comments about competitive pricing.

06 Quick answers

In one breath

What does Globus Medical actually sell?

Globus sells medical devices for spine surgery, trauma care, neurosurgery, and chronic pain. Its main products are spine implants and the robotic and navigation systems that help surgeons place them.

Why does the robot matter if implants make most of the money?

The robot can make surgeons more likely to use Globus implants during procedures. That is called implant pull-through, which means one system placement can lead to repeat implant sales over time.

What is the main reason investors are watching Nevro?

Nevro moved to earnings accretion faster than planned, but its sales are still uneven. Investors need to see revenue stabilize in the second half of 2026 before treating the deal as fully fixed.

Is Globus Medical mainly a U.S. company?

Yes. In Q1 2026, U.S. net sales were $604.9 million, while international net sales were $155.0 million. International was still meaningful at about 20.4% of total net sales.